Lung Cancer Therapeutics Market by Therapy, Type, and Geography - Forecast and Analysis 2023-2027

Published: Nov 2022 Pages: 164 SKU: IRTNTR71021

Lung Cancer Therapeutics Market Analysis Report 2023-2027: 

The global lung cancer therapeutics market size is estimated to increase by USD 10,204.33 million growing at a CAGR of 7.92% between 2022 and 2027. The  growth of the market depends on several factors, including the strong prevalence of lung cancer, the heavy contribution of immunomodulatory, and an increasing number of patient assistance programs. The global lung cancer therapeutics market has multiple approved drugs available for the treatment of NSCLC and six approved therapies for SCLC. The market witnesses the presence of many pharmaceutical giants, including Novartis AG, Pfizer Inc., AstraZeneca Plc, F. Hoffmann La Roche Ltd, and Merck and Co., Inc. These large pharmaceutical vendors are currently competing to become the market leader as these vendors account for approximately 60% of the market revenue. 

This market report extensively covers market segmentation by therapy (targeted therapy, immunotherapy, and chemotherapy), type (NSCLC and SCLC), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the size of the Lung Cancer Therapeutics Market During the Forecast Period?

To learn more about this report, Vew FREE Report Sample

Lung Cancer Therapeutics Market: Key Drivers, Trends, Challenges, and Customer Landscape

The strong prevalence of lung cancer is driving market growth, although factors such as adherence to available alternatives may impede market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Lung Cancer Therapeutics Market Driver 

The strong prevalence of lung cancer is notably driving market growth. Lung cancer is one of the most common cancer types. The new cases of cancer, especially lung cancer, have increased significantly in recent years, owing to factors such as the growth of the geriatric population and lifestyle changes. The risk of a person developing lung cancer is approximately 6.2% of the overall population in the US. Despite the reduction in the mortality rate in recent years, the mortality rate of lung cancer is still significantly high, which creates an opportunity for vendors in the market.

The increasing need for treatments, along with the advances in therapeutics such as immunotherapy and chemotherapy, is leading to more patients undergoing treatments using therapeutics. Moreover, the pipeline witnesses the strong presence of advanced therapeutics, and the proven efficacy of these therapeutics is leading to their quick approval in the clinical stages. Owing to the strong incidence rate of the disease and the increasing drug approvals, the market is expected to grow during the forecast period.

Key Lung Cancer Therapeutics Market Trends

Increasing strategic alliances is the key trend in the lung cancer therapeutics market. The market has witnessed a significant increase in the number of strategic alliances for the development and commercialization of drugs for the treatment of both NSCLC and SCLC.

In February 2019, GlaxoSmithKline Plc. and Merck and Co. Inc collaborated to codevelop and co-commercialize M7824, a bifunctional fusion protein immunotherapy, for the treatment of NSCLC. The increasing number of strategic alliances between the vendors is expected to result in the launch of advanced therapies, thereby driving the growth of the market during the forecast period.

Key Lung Cancer Therapeutics Market Challenge

Adherence to available alternatives is the major challenge impeding market growth. Surgery and radiation therapy are the most-preferred treatment options for patients with NSCLC during the early stages. Therapeutics are not highly effective during the early stages of the disease. The need for the long-term use of therapeutics is another reason for the strong preference for surgeries and radiation therapy during the early stages. Factors such as technological advances in radiation therapy are also posing a threat to the growth of the market.

For instance, the CyberKnife software allows doctors to destroy tumours with heavy doses of radiation in about four radiation therapy sessions. Another factor that poses a threat to the growth of the market is advances in diagnostic methods for the detection of lung cancer. These advances are leading to the early detection of lung cancer and resulting in the increasing use of surgeries and radiation therapy for the treatment of the disease. Thus, increasing patient adherence to the available alternatives is expected to limit the growth of the market during the forecast period.

Key Lung Cancer Therapeutics Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Lung Cancer Therapeutics Market Customer Landscape

Who are the Major Lung Cancer Therapeutics Market Vendors?

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

F. Hoffmann La Roche Ltd. - The company offers lung cancer therapeutics, namely Libtayo, under the therapeutics segment as its key offerings. Through the pharmaceuticals segment, the company manufactures essential drugs for serious diseases like cancer and others like viral infections, metabolic and central nervous system disorders, and inflammatory diseases. Through the medical device segment, the company manufactures equipment and reagents for research and medical diagnostic applications.

The global lung cancer therapeutics market report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bristol Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • Eli Lilly and Co.
  • Galecto Inc.
  • GlaxoSmithKline Plc
  • IOVANCE Biotherapeutics Inc.
  • Johnson and Johnson
  • Merck and Co. Inc.
  • Moderna Inc.
  • Novartis AG
  • Parexel International Corp.

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Lung Cancer Therapeutics Market?

The market share growth of the targeted therapy segment will be significant during the forecast period. The targeted therapy segment includes drugs that target tumor blood vessel growth (CYRAMZA) and cells with EGFR gene mutations. The growth of the segment can be attributed to the recent approval of new drugs for the treatment of lung cancer. For instance, in April 2020, Takeda Pharmaceutical Co. Ltd. received the breakthrough therapy designation (BTD) for Mobocertinib (TAK-788) from the US FDA for the treatment of NSCLC patients with EGFR Exon 20 Insertion Mutations.

Get a glance at the market contribution of various segments  Request a PDF Sample

The targeted therapy segment was valued at USD 9,077.05 million in 2017 and continued to grow until 2021. Market growth was driven by the strong drug pipeline that targeted first-line treatments for patients with lung cancer. Many other immune checkpoints inhibitors such as cemiplimab and tislelizumab and combination therapies such as ipilimumab with tremelimumab are expected to get approval during the forecast period.

Which are the Key Regions for the Lung Cancer Therapeutics Market?

For more insights on the market share of various regions Request PDF Sample now!

North America is projected to hold a 47% share of the market by 2023. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

North America accounts for the largest revenue share of the global market. This is primarily due to the high sales of approved therapeutics and the increasing prevalence of NSCLC and SCLC in the region. According to the National Institutes of Health (NIH), despite the decrease in the incidence rate of lung cancer in the US, the overall prevalence of the disease has increased significantly in recent years. However, the incidence rate and the mortality rate of the disease are still very high. They are expected to be key factors that will drive the growth of the market in the region during the forecast period.

Advances in research on drugs in clinical trial stages are expected to result in significant growth of the market in the region during the forecast period. The presence of an advanced healthcare system and the increasing number of patient assistance programs by various large pharmaceutical vendors will also support the growth of the market.

The outbreak of COVID-19 has adversely affected the US in the region. However, the outbreak in 2020 prompted vendors to come up with new business strategies to deal with the impact. They are implementing various strategies such as new product launches, M&A, and collaborations to enhance the growth of the market. For instance, in May 2020, Novartis AG launched Tabrecta, which was approved by US FDA. Tabrecta is the first and only therapy for specifically targeting metastatic NSCLC with a mutation that leads to MET exon14 (METex14), as detected by an FDA-approved test. The market in North America is expected to witness an accelerating growth momentum during the forecast period owing to all these factors.

Segment Overview

The global lung cancer therapeutics market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. The market has been segmented by therapy, type, and region.

  • Therapy Outlook (USD Million, 2017 - 2027)
    • Targeted therapy
    • Immunotherapy
    • Chemotherapy
  • Type Outlook (USD Million, 2017 - 2027)
    • NSCLC
    • SCLC
  • Region Outlook (USD Million, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
      • Singapore
    • Rest of World (ROW)
      • Brazil
      • Argentina
      • Rest of the Middle East & Africa

Parent Market Analysis

The reports categorize the global lung cancer therapeutics market as a part of the global pharmaceuticals market. The global pharmaceuticals market, the parent market, covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Our research report has extensively covered external factors influencing the parent market growth during the forecast period.

Lung Cancer Therapeutics Market Scope

Report Coverage

Details

Page number

164

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 7.92%

Market growth 2023-2027

USD 10,204.33 million

Market structure

Concentrated

YoY growth (%)

6.7

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 47%

Key countries

US, Canada, UK, France, and China

Competitive landscape

 Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Galecto Inc., GlaxoSmithKline Plc, IOVANCE Biotherapeutics Inc., Johnson and Johnson, Merck and Co. Inc., Moderna Inc., Novartis AG, Parexel International Corp., Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., F. Hoffmann La Roche Ltd., and Boehringer Ingelheim International GmbH

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Get access to Report Sample PDF !

What are the Key Data Covered in this Lung Cancer Therapeutics Market research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the market between 2023 and 2027
  • Precise estimation of the lung cancer therapeutics market size and its contribution to the parent market
  • Accurate predictions about upcoming trends and changes in consumer behaviour
  • Growth of the industry across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive analysis of factors that will challenge the growth of lung cancer therapeutics market vendors

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapy
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global lung cancer therapeutics market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global lung cancer therapeutics market 2017 - 2021 ($ million)
    • 4.2 Therapy Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Therapy Segment 2017 - 2021 ($ million)
    • 4.3 Type Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Type Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Therapy

    • 6.1 Market segments
      • Exhibit 30: Chart on Therapy - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Therapy - Market share 2022-2027 (%)
    • 6.2 Comparison by Therapy
      • Exhibit 32: Chart on Comparison by Therapy
      • Exhibit 33: Data Table on Comparison by Therapy
    • 6.3 Targeted therapy - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Targeted therapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Targeted therapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Targeted therapy - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Targeted therapy - Year-over-year growth 2022-2027 (%)
    • 6.4 Immunotherapy - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Immunotherapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on Immunotherapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on Immunotherapy - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Immunotherapy - Year-over-year growth 2022-2027 (%)
    • 6.5 Chemotherapy - Market size and forecast 2022-2027
      • Exhibit 42: Chart on Chemotherapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 43: Data Table on Chemotherapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 44: Chart on Chemotherapy - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on Chemotherapy - Year-over-year growth 2022-2027 (%)
    • 6.6 Market opportunity by Therapy
      • Exhibit 46: Market opportunity by Therapy ($ million)

    7 Market Segmentation by Type

    • 7.1 Market segments
      • Exhibit 47: Chart on Type - Market share 2022-2027 (%)
      • Exhibit 48: Data Table on Type - Market share 2022-2027 (%)
    • 7.2 Comparison by Type
      • Exhibit 49: Chart on Comparison by Type
      • Exhibit 50: Data Table on Comparison by Type
    • 7.3 NSCLC - Market size and forecast 2022-2027
      • Exhibit 51: Chart on NSCLC - Market size and forecast 2022-2027 ($ million)
      • Exhibit 52: Data Table on NSCLC - Market size and forecast 2022-2027 ($ million)
      • Exhibit 53: Chart on NSCLC - Year-over-year growth 2022-2027 (%)
      • Exhibit 54: Data Table on NSCLC - Year-over-year growth 2022-2027 (%)
    • 7.4 SCLC - Market size and forecast 2022-2027
      • Exhibit 55: Chart on SCLC - Market size and forecast 2022-2027 ($ million)
      • Exhibit 56: Data Table on SCLC - Market size and forecast 2022-2027 ($ million)
      • Exhibit 57: Chart on SCLC - Year-over-year growth 2022-2027 (%)
      • Exhibit 58: Data Table on SCLC - Year-over-year growth 2022-2027 (%)
    • 7.5 Market opportunity by Type
      • Exhibit 59: Market opportunity by Type ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 61: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 62: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 63: Chart on Geographic comparison
      • Exhibit 64: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 65: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 66: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 67: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 68: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 69: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 70: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 71: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 72: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 73: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 74: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 75: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 76: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 81: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 82: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 83: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 84: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 UK - Market size and forecast 2022-2027
      • Exhibit 85: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 86: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 87: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 88: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.9 Canada - Market size and forecast 2022-2027
      • Exhibit 89: Chart on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 90: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 91: Chart on Canada - Year-over-year growth 2022-2027 (%)
      • Exhibit 92: Data Table on Canada - Year-over-year growth 2022-2027 (%)
    • 9.10 China - Market size and forecast 2022-2027
      • Exhibit 93: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 94: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 95: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 96: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.11 France - Market size and forecast 2022-2027
      • Exhibit 97: Chart on France - Market size and forecast 2022-2027 ($ million)
      • Exhibit 98: Data Table on France - Market size and forecast 2022-2027 ($ million)
      • Exhibit 99: Chart on France - Year-over-year growth 2022-2027 (%)
      • Exhibit 100: Data Table on France - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 101: Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 102: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 103: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 104: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 105: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 106: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 107: Matrix on vendor position and classification
            • 12.3 AbbVie Inc.
              • Exhibit 108: AbbVie Inc. - Overview
              • Exhibit 109: AbbVie Inc. - Product / Service
              • Exhibit 110: AbbVie Inc. - Key offerings
            • 12.4 Amgen Inc.
              • Exhibit 111: Amgen Inc. - Overview
              • Exhibit 112: Amgen Inc. - Product / Service
              • Exhibit 113: Amgen Inc. - Key offerings
            • 12.5 Astellas Pharma Inc.
              • Exhibit 114: Astellas Pharma Inc. - Overview
              • Exhibit 115: Astellas Pharma Inc. - Product / Service
              • Exhibit 116: Astellas Pharma Inc. - Key news
              • Exhibit 117: Astellas Pharma Inc. - Key offerings
            • 12.6 AstraZeneca Plc
              • Exhibit 118: AstraZeneca Plc - Overview
              • Exhibit 119: AstraZeneca Plc - Product / Service
              • Exhibit 120: AstraZeneca Plc - Key news
              • Exhibit 121: AstraZeneca Plc - Key offerings
            • 12.7 Boehringer Ingelheim International GmbH
              • Exhibit 122: Boehringer Ingelheim International GmbH - Overview
              • Exhibit 123: Boehringer Ingelheim International GmbH - Business segments
              • Exhibit 124: Boehringer Ingelheim International GmbH - Key news
              • Exhibit 125: Boehringer Ingelheim International GmbH - Key offerings
              • Exhibit 126: Boehringer Ingelheim International GmbH - Segment focus
            • 12.8 Bristol Myers Squibb Co.
              • Exhibit 127: Bristol Myers Squibb Co. - Overview
              • Exhibit 128: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 129: Bristol Myers Squibb Co. - Key offerings
            • 12.9 Daiichi Sankyo Co. Ltd.
              • Exhibit 130: Daiichi Sankyo Co. Ltd. - Overview
              • Exhibit 131: Daiichi Sankyo Co. Ltd. - Business segments
              • Exhibit 132: Daiichi Sankyo Co. Ltd. - Key news
              • Exhibit 133: Daiichi Sankyo Co. Ltd. - Key offerings
              • Exhibit 134: Daiichi Sankyo Co. Ltd. - Segment focus
            • 12.10 Eli Lilly and Co.
              • Exhibit 135: Eli Lilly and Co. - Overview
              • Exhibit 136: Eli Lilly and Co. - Product / Service
              • Exhibit 137: Eli Lilly and Co. - Key offerings
            • 12.11 F. Hoffmann La Roche Ltd.
              • Exhibit 138: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 139: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 140: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 141: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 142: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.12 GlaxoSmithKline Plc
              • Exhibit 143: GlaxoSmithKline Plc - Overview
              • Exhibit 144: GlaxoSmithKline Plc - Business segments
              • Exhibit 145: GlaxoSmithKline Plc - Key offerings
              • Exhibit 146: GlaxoSmithKline Plc - Segment focus
            • 12.13 Merck and Co. Inc.
              • Exhibit 147: Merck and Co. Inc. - Overview
              • Exhibit 148: Merck and Co. Inc. - Business segments
              • Exhibit 149: Merck and Co. Inc. - Key news
              • Exhibit 150: Merck and Co. Inc. - Key offerings
              • Exhibit 151: Merck and Co. Inc. - Segment focus
            • 12.14 Novartis AG
              • Exhibit 152: Novartis AG - Overview
              • Exhibit 153: Novartis AG - Business segments
              • Exhibit 154: Novartis AG - Key offerings
              • Exhibit 155: Novartis AG - Segment focus
            • 12.15 Pfizer Inc.
              • Exhibit 156: Pfizer Inc. - Overview
              • Exhibit 157: Pfizer Inc. - Product / Service
              • Exhibit 158: Pfizer Inc. - Key news
              • Exhibit 159: Pfizer Inc. - Key offerings
            • 12.16 Sanofi SA
              • Exhibit 160: Sanofi SA - Overview
              • Exhibit 161: Sanofi SA - Business segments
              • Exhibit 162: Sanofi SA - Key news
              • Exhibit 163: Sanofi SA - Key offerings
              • Exhibit 164: Sanofi SA - Segment focus
            • 12.17 Takeda Pharmaceutical Co. Ltd.
              • Exhibit 165: Takeda Pharmaceutical Co. Ltd. - Overview
              • Exhibit 166: Takeda Pharmaceutical Co. Ltd. - Product / Service
              • Exhibit 167: Takeda Pharmaceutical Co. Ltd. - Key news
              • Exhibit 168: Takeda Pharmaceutical Co. Ltd. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 169: Inclusions checklist
                • Exhibit 170: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 171: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 172: Research methodology
                • Exhibit 173: Validation techniques employed for market sizing
                • Exhibit 174: Information sources
              • 13.5 List of abbreviations
                • Exhibit 175: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              lung cancer therapeutics market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis